For instance, the IDO1 inhibitor, LY3381916, combined with the PD-L1 inhibitor, can minimize the activity of IDO1, eventually increasing the number of T cells and promoting anti-tumor immunity (15). This evidence concerns the gene IDO1 and neoplasm.